Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes
Main finding · All-cause deathResult — go to the resultHazard ratio 0.61 95% CI 0.50–0.75Authors' conclusion
Oral semaglutide appeared to be associated with a lower 1-year risk of all-cause death compared with sitagliptin in patients with HFpEF and T2D.
Study context
- Population
- Patients aged ≥18 years with heart failure with preserved ejection fraction (HFpEF) and T2D initiating oral semaglutide or sitagliptin between October 1, 2019, and December 31, 2023, TriNetXpropensity-score matched
- Participants
- 3,452 vs 3,452
- Exposure
- Oral semaglutide vs sitagliptin
- Oral semaglutiden = 3,452
- Sitagliptinn = 3,452reference
- Outcome
- All-cause death
- Follow-up
- 1 year
Methodological detailsmulticentre, propensity-score matched, TriNetX research network
- Multicentre
- Propensity-score matched
- TriNetX research network
Main finding
As reported in the abstract
Hazard ratio
0.61
95% CI 0.50–0.75
log-rank p < 0.001
Events by group
Oral semaglutidevs Sitagliptin
HR 0.61 (95% CI 0.50–0.75); log-rank p < 0.001
Observational data: associations, not effects.
Secondary outcomes
| Outcome | Oral semaglutide | Sitagliptin | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Hospitalisation · 1 year | 37.1% | 42.4% | 0.83 (0.77–0.90) | log-rank p < 0.001 | |
| 0.512Hazard ratio (log scale) |
Original publication
Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes. Diabetes Obes Metab. Published 5 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →